MX2021014938A - Inhibidores de aldosa reductasa y metodos de uso. - Google Patents
Inhibidores de aldosa reductasa y metodos de uso.Info
- Publication number
- MX2021014938A MX2021014938A MX2021014938A MX2021014938A MX2021014938A MX 2021014938 A MX2021014938 A MX 2021014938A MX 2021014938 A MX2021014938 A MX 2021014938A MX 2021014938 A MX2021014938 A MX 2021014938A MX 2021014938 A MX2021014938 A MX 2021014938A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- disorders
- skin
- diabetic
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000003288 aldose reductase inhibitor Substances 0.000 title 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000451 tissue damage Effects 0.000 abstract 2
- 231100000827 tissue damage Toxicity 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 230000007166 healthy aging Effects 0.000 abstract 1
- 210000005003 heart tissue Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000037906 ischaemic injury Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Cosmetics (AREA)
Abstract
La presente divulgación se refiere a nuevos compuestos y composiciones farmacéuticas de los mismos, así como a métodos para favorecer el envejecimiento saludable de la piel, el tratamiento de trastornos de la piel, el tratamiento de enfermedades cardiovasculares, el tratamiento de trastornos renales, el tratamiento de trastornos relacionados con la angiogénesis, como el cáncer, el tratamiento de lesiones tisulares, como daños a los tejidos no cardíacos, el tratamiento del infarto de miocardio en evolución, el tratamiento de la lesión isquémica y el tratamiento de varios otros trastornos, como las complicaciones derivadas de la diabetes, por medio de los compuestos y composiciones de la invención. Otros trastornos pueden incluir, de manera enunciativa mas no limitativa, ateroesclerosis, enfermedad coronaria, nefropatía diabética, neuropatía diabética, retinopatía diabética, cardiomiopatía diabética, infecciones de la piel, enfermedad vascular periférica, accidente cerebrovascular, asma, y otros similares.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662352784P | 2016-06-21 | 2016-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021014938A true MX2021014938A (es) | 2022-01-24 |
Family
ID=60783884
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018016122A MX2018016122A (es) | 2016-06-21 | 2017-06-21 | Inhibidores de aldosa reductasa y metodos de uso. |
MX2021014938A MX2021014938A (es) | 2016-06-21 | 2018-12-18 | Inhibidores de aldosa reductasa y metodos de uso. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018016122A MX2018016122A (es) | 2016-06-21 | 2017-06-21 | Inhibidores de aldosa reductasa y metodos de uso. |
Country Status (23)
Country | Link |
---|---|
US (5) | US10150779B2 (es) |
EP (3) | EP3352754B1 (es) |
JP (3) | JP6895464B2 (es) |
CN (2) | CN109310674B (es) |
AU (3) | AU2017281082B2 (es) |
BR (1) | BR112018076244A2 (es) |
CA (1) | CA3025081A1 (es) |
DK (2) | DK3757107T3 (es) |
ES (2) | ES2966094T3 (es) |
FI (1) | FI3757107T3 (es) |
HK (1) | HK1259379A1 (es) |
HR (2) | HRP20231563T1 (es) |
HU (2) | HUE052101T2 (es) |
IL (3) | IL304979A (es) |
LT (2) | LT3757107T (es) |
MX (2) | MX2018016122A (es) |
PL (1) | PL3757107T3 (es) |
PT (2) | PT3352754T (es) |
RS (1) | RS61239B1 (es) |
SG (2) | SG11201810642XA (es) |
SI (2) | SI3352754T1 (es) |
WO (1) | WO2017223179A1 (es) |
ZA (1) | ZA201808506B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
DK3757107T3 (da) * | 2016-06-21 | 2023-11-27 | Univ Columbia | 4-oxo-3,4-dihydrothieno[3,4-d]pyridazinforbindelser som aldosereduktasehæmmere og metoder til anvendelse deraf |
CA3071114A1 (en) * | 2017-07-28 | 2019-01-31 | Applied Therapeutics Inc. | Compositions and methods for treating galactosemia |
WO2020167937A1 (en) * | 2019-02-12 | 2020-08-20 | Applied Therapeutics, Inc. | Methods for treating cutaneous aging |
SG11202110590PA (en) * | 2019-04-01 | 2021-10-28 | Applied Therapeutics Inc | Inhibitors of aldose reductase |
CA3153108A1 (en) * | 2019-10-08 | 2021-04-15 | Riccardo Perfetti | Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency |
EP4125909A1 (en) | 2020-03-31 | 2023-02-08 | Applied Therapeutics Inc. | Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy |
CA3176768A1 (en) | 2020-05-01 | 2021-11-04 | Shoshana SHENDELMAN | Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency |
US20240033263A1 (en) * | 2021-03-18 | 2024-02-01 | Banavara MYLARI | Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0189272A3 (en) * | 1985-01-17 | 1987-08-19 | Fujisawa Pharmaceutical Co., Ltd. | New furanone derivatives, processes for preparation thereof and use thereof |
CA1299178C (en) | 1985-11-07 | 1992-04-21 | Banavara Lakshmana Mylari | Heterocyclic oxophtalazinyl acetic acids |
US4939140A (en) | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
ES2032749T3 (es) | 1985-11-07 | 1993-03-01 | Pfizer Inc. | Acidos oxoftalazinil-aceticos heterociclicos. |
US4868301A (en) * | 1987-06-09 | 1989-09-19 | Pfizer Inc. | Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains |
WO1989006651A1 (en) * | 1988-01-19 | 1989-07-27 | Pfizer Inc. | 1h-indazole-3-acetic acids as aldose reductase inhibitors |
US4996204A (en) | 1989-05-11 | 1991-02-26 | Pfizer Inc. | Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors |
US4954629A (en) | 1989-05-11 | 1990-09-04 | Pfizer Inc. | Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof |
FR2647676A1 (fr) | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase |
US5304557A (en) | 1989-12-15 | 1994-04-19 | Pfizer Inc. | Substituted oxoophthalazinyl acetic acids and analogs thereof |
JPH0495025A (ja) | 1990-08-08 | 1992-03-27 | Asahi Chem Ind Co Ltd | アルドースリダクターゼ阻害剤 |
AU683620B2 (en) * | 1992-09-28 | 1997-11-20 | Pfizer Inc. | Substituted pyrimidines for control of diabetic complications |
CN1200106A (zh) | 1995-08-28 | 1998-11-25 | 美国家用产品公司 | 苯氧基乙酸类化合物用作醛糖还原酶抑制剂和抗高血糖药 |
US6169087B1 (en) | 1997-09-23 | 2001-01-02 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPases) |
ID27884A (id) | 1998-03-31 | 2001-05-03 | Inst For Pharm Discovery Inc | Asam-asam indolealkanoat yang disubstitusikan. |
EP0982306A3 (en) | 1998-08-21 | 2000-07-05 | Pfizer Products Inc. | Polymorph of zopolrestat monohydrate |
US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
ES2231681T3 (es) | 2001-03-30 | 2005-05-16 | Pfizer Products Inc. | Inhibidores de piridazinona de la aldosa reductasa. |
DE60308996T2 (de) | 2002-01-23 | 2007-05-10 | Eli Lilly And Co., Indianapolis | Melanocortinrezeptoragonisten |
US20040047919A1 (en) | 2002-06-13 | 2004-03-11 | Board Of Regents, The University Of Texas System | Methods and compositions involving aldose reductase inhibitors |
AU2003242390A1 (en) * | 2002-06-14 | 2003-12-31 | Takeda Pharmaceutical Company Limited | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers |
US7572910B2 (en) | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
US20070021366A1 (en) | 2004-11-19 | 2007-01-25 | Srivastava Satish K | Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use |
CN101143868A (zh) | 2007-09-04 | 2008-03-19 | 北京理工大学 | 醛糖还原酶抑制剂结构及用途 |
RS63796B1 (sr) | 2010-07-16 | 2022-12-30 | Univ Columbia | Inhibitori aldoza reduktaze i njihova upotreba |
US8916563B2 (en) * | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
CN102512407B (zh) | 2011-11-23 | 2014-05-21 | 中山大学 | 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用 |
DK3757107T3 (da) | 2016-06-21 | 2023-11-27 | Univ Columbia | 4-oxo-3,4-dihydrothieno[3,4-d]pyridazinforbindelser som aldosereduktasehæmmere og metoder til anvendelse deraf |
US11329472B2 (en) | 2018-07-20 | 2022-05-10 | Texas Instruments Incorporated | Methods and apparatus to prevent undesired triggering of short circuit or over current protection |
-
2017
- 2017-06-21 DK DK20188323.8T patent/DK3757107T3/da active
- 2017-06-21 ES ES20188323T patent/ES2966094T3/es active Active
- 2017-06-21 HU HUE17816127A patent/HUE052101T2/hu unknown
- 2017-06-21 ES ES17816127T patent/ES2836500T3/es active Active
- 2017-06-21 SI SI201730529T patent/SI3352754T1/sl unknown
- 2017-06-21 IL IL304979A patent/IL304979A/en unknown
- 2017-06-21 WO PCT/US2017/038505 patent/WO2017223179A1/en active Application Filing
- 2017-06-21 LT LTEP20188323.8T patent/LT3757107T/lt unknown
- 2017-06-21 HU HUE20188323A patent/HUE064911T2/hu unknown
- 2017-06-21 PT PT178161279T patent/PT3352754T/pt unknown
- 2017-06-21 CN CN201780038647.5A patent/CN109310674B/zh active Active
- 2017-06-21 MX MX2018016122A patent/MX2018016122A/es unknown
- 2017-06-21 IL IL283809A patent/IL283809B2/en unknown
- 2017-06-21 EP EP17816127.9A patent/EP3352754B1/en active Active
- 2017-06-21 FI FIEP20188323.8T patent/FI3757107T3/fi active
- 2017-06-21 BR BR112018076244-0A patent/BR112018076244A2/pt active Search and Examination
- 2017-06-21 EP EP20188323.8A patent/EP3757107B1/en active Active
- 2017-06-21 HR HRP20231563TT patent/HRP20231563T1/hr unknown
- 2017-06-21 SG SG11201810642XA patent/SG11201810642XA/en unknown
- 2017-06-21 CN CN202210711329.3A patent/CN115160339B/zh active Active
- 2017-06-21 DK DK17816127.9T patent/DK3352754T3/da active
- 2017-06-21 JP JP2018567299A patent/JP6895464B2/ja active Active
- 2017-06-21 SI SI201731462T patent/SI3757107T1/sl unknown
- 2017-06-21 SG SG10202012188VA patent/SG10202012188VA/en unknown
- 2017-06-21 CA CA3025081A patent/CA3025081A1/en active Pending
- 2017-06-21 EP EP23201547.9A patent/EP4316603A3/en active Pending
- 2017-06-21 PT PT201883238T patent/PT3757107T/pt unknown
- 2017-06-21 LT LTEP17816127.9T patent/LT3352754T/lt unknown
- 2017-06-21 AU AU2017281082A patent/AU2017281082B2/en active Active
- 2017-06-21 RS RS20201463A patent/RS61239B1/sr unknown
- 2017-06-21 PL PL20188323.8T patent/PL3757107T3/pl unknown
-
2018
- 2018-04-24 US US15/961,288 patent/US10150779B2/en active Active
- 2018-11-06 US US16/182,169 patent/US10647726B2/en active Active
- 2018-12-10 IL IL263631A patent/IL263631B/en unknown
- 2018-12-18 ZA ZA2018/08506A patent/ZA201808506B/en unknown
- 2018-12-18 MX MX2021014938A patent/MX2021014938A/es unknown
-
2019
- 2019-01-31 HK HK19101747.3A patent/HK1259379A1/zh unknown
-
2020
- 2020-03-31 US US16/835,876 patent/US10870658B2/en active Active
- 2020-11-02 US US17/086,699 patent/US11498925B2/en active Active
- 2020-11-30 HR HRP20201905TT patent/HRP20201905T1/hr unknown
-
2021
- 2021-06-07 JP JP2021094883A patent/JP7368419B2/ja active Active
- 2021-06-09 AU AU2021203801A patent/AU2021203801B2/en active Active
-
2022
- 2022-10-13 US US18/046,205 patent/US20230312599A1/en active Pending
-
2023
- 2023-06-30 AU AU2023204218A patent/AU2023204218A1/en active Pending
- 2023-10-12 JP JP2023176883A patent/JP2023171614A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021014938A (es) | Inhibidores de aldosa reductasa y metodos de uso. | |
WO2016172134A3 (en) | Novel compounds | |
WO2017087901A3 (en) | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies | |
EA201890570A1 (ru) | [4-(1,3,3-триметил-2-оксо-3,4-дигидро-1h-хиноксалин-7-ил)фенокси]этилокси соединение или его соль | |
WO2015168466A8 (en) | Inhibitors of lysine specific demethylase-1 | |
MX2020010496A (es) | Inhibidores de desmetilasa-1 especifica de lisina. | |
MX2017002824A (es) | Inhibidores demetilasa-1 especifica de lisina. | |
EA201791070A1 (ru) | Способы получения ингибиторов ask1 | |
MX2017000179A (es) | Inhibidores de demetilasa-1 especifica de lisina. | |
MX2018005096A (es) | Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular. | |
TW201613932A (en) | Organic compounds | |
MX2020010900A (es) | Inhibidores de demetilasa-1 especifica de lisina. | |
UY33288A (es) | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico | |
CU20200084A7 (es) | Derivados sustituidos de la carboxamida dihidropirazolo pirazina | |
MX2017000170A (es) | Inhibidores de demetilasa-1 especifica de lisina. | |
WO2011133659A3 (en) | Inhibitors of hif and angiogenesis | |
EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения | |
NZ729600A (en) | Binding proteins specific for lox1 and uses thereof | |
BR112017004173A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica. | |
EA201891143A1 (ru) | Пиперидиноновые агонисты формилпептидного рецептора 2 и формилпептидного рецептора 1 | |
NO20180002A1 (en) | Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors | |
PH12021550872A1 (en) | Therapeutic compounds | |
MX2021011858A (es) | Inhibidores de aldosa reductasa. | |
PH12019501108A1 (en) | Anti-gitr anti-binding protein and methods of use thereof | |
PH12015502523A1 (en) | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |